Impact of Face Masks on 6-Minute Walk Test in Healthy Volunteers

Kevin M Swiatek, Charnetta Lester, Nicole Ng, Saahil Golia, Janet Pinson, Dan Grinnan, Kevin M Swiatek, Charnetta Lester, Nicole Ng, Saahil Golia, Janet Pinson, Dan Grinnan

Abstract

Our objective was to establish the impact of wearing a face mask on the outcome of six-minute walk test in healthy volunteers. In a study of 20 healthy volunteers who each completed two 6MWTs, one with a mask and one without, there was no difference in distance walked. However, there was a significant difference in perception of dyspnea between the two groups.

Keywords: 6-miunte walk test; COVID-19; face mask; pulmonary hypertension.

© The Author(s) 2021.

Figures

Fig. 1.
Fig. 1.
Impact of Facemask on 6MWD and Borg Score. 6MWD: 6-minute walk distance.

References

    1. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.
    1. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231–1237.
    1. Cahalin LP, Mathier M, Semigran MJ, et al. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 1996; 110 (2): 325–332.
    1. Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301.
    1. Galie N, Ghofrani H, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.
    1. Rubin L, Badesch D, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.
    1. Benza R, Gomberg-Mailtland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest 2019; 156: 323–337.
    1. Galie N, Humbert M, Vachiery J, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force. Eur Heart J 2016; 37: 67–119.
    1. Holland A, Spruit M, Troosters R, et al. An official ERS/ATS technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44: 1428–1446.
    1. ATS BOARD OF DIRECTORS, ATS Statement: Guidelines for the six-minute walk test this official statement of the American Thoracic Society. Am J Respir Crit Care Med 2002; 166: 111–117.
    1. Matura LA, McDonough A, Carroll DL. Symptom prevalence, symptom severity, and health-related quality of life among young, middle, and older adults with pulmonary arterial hypertension. Am J Hospice Palliative Med 2016; 33: 214–221.
    1. Khair RM, Nwaneri C, Damico RL, et al. The minimal important difference in borg dyspnea score in pulmonary arterial hypertension. Ann Am Thorac Soc 2016; 13: 842–849.
    1. Samannan R, Holt G, Calderon-Candelario R, et al. Effect of face masks on gas exchange in health persons and patients with COPD. Ann of Am Thorac Soc 2020. doi:10.1513/annalsats.202007-812rl
    1. Person E, Lemercier C, Royer A, et al. Effet du port d’un masque de soins lors d’un test de marche de six minutes chez des sujets sains [Effect of a surgical mask on six minute walking distance]. Rev Mal Respir 2018; 35: 264–268.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa